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INTRODUCTION
Aspirin (ASA) and non-steroidal anti-inflammatory drugs
(NSAIDs) cause bronchoconstriction in 10-20% of adult asth-
matics (1). ASA-induced bronchoconstriction is more com-
mon in female patients with non-atopic asthma (57% vs.
43% in North America, 73% vs. 27% in Korea) and is asso-
ciated with acute or chronic rhinosinusitis and/or nasal polyps
in 60-80% of patients (2, 3). Seventy-nine percent of these
patients require long-term oral or inhaled corticosteroid ther-
apy for symptom control (4).
The mechanism of ASA-induced bronchoconstriction is
not yet fully understood. It is widely accepted that ASA and
NSAIDs block the cyclooxygenase pathway, which causes
arachidonate substrates to be diverted to the 5-lipoxygenase
pathway (5). A recent review has emphasized the importance
of chronic overproduction of cysteinyl leukotriene (5). Down-
regulation of cyclooxygenase-2 and prostaglandin E2 may
also accelerate cysteinyl leukotriene production (5, 6). 
On the other hand, organ- and non-organ-specific autoan-
tibodies have been described in asthmatics by several inves-
tigators (7-9). It has also been suggested that non-atopic
patients have an increased incidence of autoantibodies and a
higher tendency to have accompanying autoimmune diseases,
which include rheumatoid arthritis, Sjogren’s syndrome, and
autoimmune thyroiditis (7). Furthermore, our previous study
(12) demonstrated that circulating IgG to bronchial epithe-
lial cells, which was identified as being directed against cytok-
eratin (CK)18, was present in the sera of patients with non-
atopic asthma. Although antinuclear antibody (ANA) and
Clq-binding immune complex (CIC) have been evaluated
previously in ASA-intolerant asthma (9), there have been no
reports on the quantification of levels of autoantibodies against
bronchial epithelial cytokeratins. Recent studies have demon-
strated that human leukocyte antigen (HLA) DPB1*0301,
which is generally accepted as a contributor to genetic sus-
ceptibility in various autoimmune diseases, is a valuable gene
marker for ASA-intolerant asthma in both Caucasian and
Oriental populations (10, 11).
In this study, to investigate the involvement of an autoim-
mune mechanism in ASA-intolerant asthma, we compared
the levels of circulating autoantibodies, which included ANA
and autoantibodies to tissue transglutaminase (TGase), CK8,
CK18, and CK19, in the sera of 79 patients with ASA-intol-
erant asthma to those in the sera of patients with ASA-toler-
ant asthma and healthy control subjects. In addition, circulat-
ing serum CIC was detected by enzyme-linked immunosor-
bent assay (ELISA).
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Circulating Autoantibodies in Patients with Aspirin-intolerant Asthma:
An Epiphenomenon Related to Airway Inflammation
Several studies have suggested the involvement of an autoimmune mechanism in
aspirin (ASA)-intolerant asthma. To test this hypothesis, we measured the levels of
circulating autoantibodies, such as IgG and IgA to tissue transglutaminase (TGase),
IgG to cytokeratins (CKs) 8, 18, and 19, Clq-binding immune complex (CIC), and
antinuclear antibody (ANA), in the sera of 79 patients with ASA-intolerant asthma
(Group I) and those of two control groups, consisting of 61 patients with ASA-toler-
ant asthma (Group II) and 88 healthy control subjects (Group III) by means of ELISA.
Significantly higher prevalences of IgG antibodies to CK18 (13.9%) and CK19 (17.7%)
were noted in Group I, as compared with Group III (p<0.05 for all) not with Group
II. Regarding the prevalences of other autoantibodies, the levels of ANA (1.3%),
IgG to TGase (3.8%), and CIC (24.7%) in Group I were not significantly different
from those in Groups II and III. Significant correlations were found between posi-
tivities for the anti-CK18 and anti-CK19 autoantibodies and the PC20 methacholine
values in the analysis of asthma Groups I and II vs. normal controls, (p=0.001 and
p=0.003, respectively). Further studies are needed to explore the potential involve-
ment of an autoantibody-mediated mechanism in the clinical manifestation of bronchial
asthma. 
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MATERIALS AND METHODS
Subjects
Seventy-nine patients with ASA-intolerant asthma (30 men
and 49 women: mean age of 46 yr), and two sex-matched
control groups: 61 patients with ASA-intolerant asthma (20
men and 41 women; mean age of 43 yr), and 88 normal healthy
controls (33 men and 55 women; mean age 36 yr), who were
enrolled at the Department of Allergy and Rheumatology,
Ajou University Hospital, Suwon, Korea.
Asthma was diagnosed according to the revised GINA
guidelines (2002), and comprised typical asthma symptoms,
reversible airway obstruction, and airway hyperresponsiveness
to methacholine. ASA-intolerant asthma was diagnosed by
positive results in the lysine-aspirin (L-ASA) bronchoprovo-
cation test (BPT). A patient was classified as having allergic
asthma if a skin prick test with at least one of fifty common
aeroallergens was positive and correlated with the clinical sym-
ptoms. In patients with non-atopic asthma, both skin prick
tests and serum-specific IgE were negative. All of the ASA-
tolerant patients showed negative responses on L-ASA BPT
and had no history of adverse reactions to ASA and NSAIDs.
The 65 healthy controls were enrolled at random from a local
population. All of the subjects gave informed consent for the
studies, and the protocols were approved by the ethics commit-
tees of Ajou University Hospital, Suwon, Korea. The demo-
graphic data on the three study groups are compared in Table 1.
Allergy skin prick test
Skin prick tests were performed with 50 common aeroaller-
gens (Bencard, Bretford, U.K.), which included Dermatopha-
goides pteronyssinus, D. farine, cat, dog, cockroach, tree pollen
mixture, grass pollen mixture, mugwort, ragweed, Humulus
japonicus, Aspergillus, Alternaria, histamine, and a saline control.
The reactions were read after 15 min, and the wheal was mea-
sured in two directions. A positive reaction was defined as a
mean wheal diameter of ≥3 mm. Atopy was determined by
a positive skin test response to at least one common inhalant
allergen.
Bronchoprovocation test with methacholine and L-ASA
The methacholine bronchoprovocation test was performed
according to the method previously described (10). Five
inhalations of normal saline at 5-min intervals were taken
followed by a series of successively doubled doses of metha-
choline (0.075-25 mg/mL) until a 20% fall in FEV1 was
observed or the maximum dose given. FEV1 was measured
5 min after the beginning of each set of inhalations of aeroso-
lized methacholine. The methacholine PC20 level was deter-
mined by interpolation from the dose-response curve. 
The L-ASA BPT was performed according to the modified
method described previously (10). All medications, includ-
ing xanthine derivatives, beta-2 agonists, and steroids, were
stopped 72 hr before the procedure. The test solutions were
delivered by a Devilbiss 646 nebulizer (DeVilbiss, Somerset,
PA, U.S.A.) connected to a compressed air source (5 L/min).
L-ASA powder (Althargyl, DongAh, Korea) that contained
900 mg L-ASA with 100 mg aminoacetic acid was diluted
in normal saline, to produce a stock solution of 300 mg/mL.
The stock solution was diluted in normal saline to produce
a range of doubling concentrations from 75 to 300 mg/mL.
A placebo solution of normal saline was used as the control.
Subjects inhaled the aerosol via a mouthpiece during normal
tidal breathing. If the baseline forced expiratory volume in
1 sec (FEV1) was >65% of the predicted value, and the change
in FEV1 was <10% after inhalation of normal saline, L-ASA
BPT was performed. The L-ASA solution was inhaled every
30 min. The FEV1 and maximum mid-expiratory flow were
measured at 10 and 30 min after each dose. The provocation
was stopped when the FEV1 had decreased >20% from the
baseline. When the change in FEV1 at 30 min after inhala-
tion of the maximum dose of L-ASA was <15%, the last dose
was inhaled once more. The FEV1 and maximum mid-expi-
ratory flow (MMEF) after the last dose were measured at 10,
30, and 60 min, and then hourly for 7 hr.
ELISA for specific IgG antibodies to CK8, CK18, and CK19
The serum-specific IgG level was detected by ELISA using
50  L of diluted (1:20) patient serum or negative control
serum. This was determined to be the optimal concentration
in the preliminary experiment, and was added to each well
of ELISA plates that had been coated with 100 ng/well of
Group I, aspirin-intolerant asthma patients; Group II, aspirin-tolerant asth-
ma patients; Group III, healthy normal controls. NA, not applicable.
Data expressed as mean±standard deviation except PC20 methacholine
was expressed as mean±standard error mean.
*p<0.001 for Group I vs. Group III, p=0.009 for Group II vs. Group III
(Dunnett’s t-test, two-sided); 
� p<0.05 (t-test); 
� p=0.035 for Group I vs.
Group III (two-sided Dunnett’s t-test, in which Group I was treated as
the control group).
Group I
n=79 (%)
Group II
n=61 (%)
Group III
n=88 (%)
Age (yr) 45.73±13.7 42.90±13.7 35.65±14.3*
Sex, female (%) 42 (62.0) 41 (67.2) 32 (49.2)
Atopy (%) 34 (44.7) 22 (36.7) NA
Duration of asthma (yr) 6.75±5.9 4.35±5.5 NA
Baseline FEV1 (%) 74.47±26.6
� 89.43±21.0 NA
PC20 methacholine 7.27±3.7
� 13.42±3.6 NA
(mg/mL)
IgG to CK8 (AU/mL) 81.00±52.2 88.13±80.3 92.73±36.5
IgG to CK18 (AU/mL) 95.65±61.3 77.98±107.6 75.92±40.1
IgG to CK19 (AU/mL) 96.67±85.9
� 80.54±70.5 69.14±32.7
Table 1. Clinical characteristics and anti-cytokeratin antibodies
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CK8, CK18, and CK19 (Research Diagnostics, Flanders, NJ,
U.S.A.) dissolved in PBS. The wells were blocked with 200
L of blocking buffer (PBS that contained 10% FBS). After
1 hr of incubation at room temperature, the plate was washed
three times with PBS-T. Alkaline phosphatase-conjugated
anti-human IgG (100  L; Sigma, St Louis, MO, U.S.A.),
which was diluted to 1:10,000 v/v with 10% FBS-PBS, was
added to the wells for 1 hr at 37℃. The wells were then
washed with PBS-T, and PNPP (p-nitrophenyl phosphate;
Sigma) was added as the substrate solution. The reactions
were stopped by the addition of 1 N NaOH. The optical
density of the solution was determined at 405 nm using an
ELISA reader. The final absorbance value was determined
by subtraction of the absorbance value of the uncoated well.
Each absorbance value is presented in arbitrary units based
on the standard curve, which was derived from serial dilutions
of the pooled serum samples with high specific levels of IgG
to CK8, CK18, and CK19, respectively. The positive cutoff
value was determined as the mean plus two standard devia-
tions (SD) of the absorbance values of the serum samples from
89 unexposed healthy control subjects.
Measurements of ANA, IgG and IgA antibodies to TGase,
and CIC levels
Serum levels of ANA, IgG and IgA antibodies to TGase,
and CIC were measured by ELISA using commercially avail-
able kits (BL-Diagnostika GmbH, Mainz, Germany), accord-
ing to the manufacturer’s instructions. 
IgG immunoblotting for CK8, CK18, and CK19
Recombinant CKs in a solution of 30 mM TrisHCl (pH
8.0), 2 mM EDTA, 9.5 M urea, 2 mM DTT, and 10 mM
methylammonium chloride were separated by discontinuous
SDS-polyacrylamide gel electrophoresis (PAGE) using a 4%
to 20% Tris-glycine gradient gel (Invitrogen, Carlsbad, CA,
U.S.A.). After electrophoresis, the proteins were transferred
onto a polyvinylidene difluoride membrane (Millipore, Bed-
ford, MA, U.S.A.) and blocked with 5% non-fat milk. After
the transfer, the membrane strips were probed with mono-
clonal antibodies to CK8, CK18, and CK19 (Sigma) at 1:20
dilutions for 3 hr at room temperature. After washing, the
strips were incubated with alkaline phosphatase-conjugated
goat anti-human IgG (Sigma) for 1 hr at room temperature.
After a final wash, the membranes were stained with the sub-
strate solution nitro-blue tetrazolium/5-bromo-4-chloro-3-
indoyl phosphate (Sigma); the intensities of the stained bands
were measured using a densitometer and presented as relative
intensities.
Statistical analysis 
The results are expressed as mean±standard deviation.
The Student’s t-test and analysis of variance (ANOVA) with
a post-hoc test (Dunnett’s) were used for comparisons between
continuous data such as age, levels of autoantibodies and CIC,
duration of asthma, baseline FEV1, and PC20 methacholine
dose. Intergroup comparisons of the prevalences of specific
IgG antibodies to the three CKs, ANA, IgG antibodies to
TGase, CIC, and clinical parameters were done with the chi
square and Fisher’s exact tests, with adjustments for multiple
comparisons. For association study between presence of auto-
antibodies and the disease-related phenotypes, we accepted
a p-value using Levene’s test for equality of variances in order
to exclude an artificial false significance. All of the described
tests were two-tailed. A p value ≤0.05 was regarded as sta-
tistically significant. The statistical analyses were performed
using the SPSS 11.0 for Windows software (SPSS Inc., Chica-
go, IL, U.S.A.)
RESULTS
Clinical characteristics of the study subjects
In Group I, 34 (45.3%) subjects had atopic tendencies
and 53 (67.6%) had chronic rhinosinusitis. The mean base-
line FEV1 value was significantly lower for Group I than for
Group II (p=0.001). However, the prevalence of atopy and
duration of asthma, as well as the PC20 methacholine doses,
showed no significant differences between the two asthma
groups (Table 1). 
Levels of IgG specific for CK8, CK18, and CK19 
There were no significant differences in the levels of IgG
to CK8 and CK18 among the three groups, while the levels
of IgG to CK19 differed significantly between Groups I and
III (Dunnett’s t-test, p=0.024). The prevalence of IgG to
CK19 (17.7%) was highest in Group I, followed by those of
IgG to CK18 (13.9%) and IgG to CK8 (8.9%). However,
statistical significance was noted only for the prevalences of
IgG to CK18 and of IgG to CK19, compared between Groups
I and III (p=0.014, p=0.020, respectively). IgG antibodies to
CK19 were significantly associated with IgG to CK8 (Pear-
Fig. 1. Separation of recombinant CKs on SDS-PAGE (CK), and
immunoblot findings using the sera of patients with ASA-intolerant
asthma (AIA), normal controls (NC), buffer (B), and monoclonal
antibodies (M) to the three cytokeratins.
CK
81 81 9
98
AIA NC B M
64
50
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son’s coefficient=0.320, p<0.001) and CK18 (Pearson’s coef-
ficient=0.442, p<0.001).
IgG immunoblotting for CK8, CK18, and CK19 
Fig. 1 shows the SDS-PAGE and IgG immunoblot find-
ings using patient sera, buffer control, negative control sera,
and monoclonal antibodies to CK8, CK18, and CK19. Spe-
cific binding to CK8, CK18, and CK19 was noted in the
sera of ASA-intolerant asthma subjects. 
Association between Anti-CK antibodies and asthma
phenotypes and the prevalences of other autoantibodies
Table 2 summarizes the relationships between the different
autoantibodies detected in the study subjects. Three (3.8%)
subjects in Group I and four (6.8%) subjects in Group II had
detectable IgG antibodies to TGase, while none of the sub-
jects in Group III had IgG antibodies to TGase. None of the
study subjects had IgA to TGase. One subject of Groups I
(1.3%) and II (1.7%), respectively had high serum levels of
ANA, while none of the subjects in Group III had serum
ANA. The prevalence of CIC was significantly higher in
Groups I (24.7%) and II (33.3%) than in Group III (0%).
However, there were no significant associations between anti-
CK antibodies and IgG to TGase, ANA, and CIC (p>0.05
for all) in Group I. In addition, no significant associations
were found between the prevalence of IgG to the three CKs
and the presence of HLA DPB1*0301 (p>0.05 for all; data
not shown). Regarding asthma phenotypes, the presence of
anti-CK18 and anti-CK19 antibodies was significantly asso-
ciated with PC20 methacholine values in the analysis with both
asthma groups (p=0.001 and p=0.003, respectively, Table 3).
However, no significant difference was noted between anti-
CKs antibodies and PC20 methacholine, baseline FEV1 in the
analysis with subjects limited to Group I.
DISCUSSION
In this study, we have demonstrated that serum anti-CK8,
anti-CK18, and anti-CK19 autoantibodies are present in
certain populations of bronchial asthma patients. The preva-
lences of anti-CK18 and anti-CK19 autoantibodies were
significantly higher in patients with ASA-intolerant asthma
than in healthy controls. While some of the ASA-tolerant
asthmatics had anti-CK18 and anti-CK19 antibodies, the
prevalences did not differ from those of normal controls. Fur-
thermore, a proportion of the asthma patients, regardless of
ASA sensitivity, had laboratory markers of autoimmunity,
including ANA, CIC, and IgG antibody to TGase, although
the prevalences of these markers were too low to be statisti-
cally significant.
The mechanism of induction of autoantibodies in asthma
remains unknown. Disruption of bronchial epithelial cells
and subsequent exposure of autoantigens or ineffective anti-
gen elimination during the inflammatory process may cause
chronic immune stimulation and autoantibody production.
In asthma, the bronchial epithelium is characteristically dam-
aged, with shedding of the columnar cells into the airway
lumen. Recently, it has been demonstrated that high doses
of acetaminophen reduce the levels of glutathione in lung
tissues (13), and that the asthmatic bronchial epithelium is
more susceptible to oxidant-induced apoptosis (14). During
this early apoptosis, activated caspases cleave a variety of struc-
tural proteins. Therefore, it may be postulated that disrup-
tion of the cytoskeleton leads to the loss of apoptotic cells
Group I, aspirin-intolerant asthma patients; Group II, aspirin-tolerant asth-
ma patients; Group III, healthy normal controls. CK, cytokeratin; TGase,
tissue transglutaminase; CIC, C1q-binding immune complex.
*p values are determined by chi-square or Fisher’s exact test with adjust-
ment for multiple comparisons. NS, not significant.
Group I
n=79 (%)
Group II
n=61 (%)
Group III
n=88 (%)
p value*
Group 
I vs. II
Group 
I vs. III
IgG to CK8 7 (8.9) 5 (8.2) 4 (4.5) NS NS
IgG to CK18 11 (13.9) 4 (6.6) 2 (2.3) NS 0.014
IgG to CK19 14 (17.7) 7 (11.5) 3 (3.4) NS 0.022
ANA 1 (1.3) 1 (1.7) 0 (0) NS NS
IgG to TGase 3 (3.8) 4 (6.7) 0 (0) NS NS
CIC 19 (24.7) 20 (33.3) 0 (0) NS NS
Table 2. Prevalences of circulating autoantibodies in the three
study groups
p 
value
IgG to CK18
Positive Negative
p 
value
IgG to CK19
Positive Negative
ANA
Positive 0 2 NS 0 2 NS
Negative 16 197 21 116
IgG to TGase
Positive 0 7 NS 2 5 NS
Negative 15 178 19 113
CIC
Positive 4 35 NS 10 29 0.035
Negative 11 87 11 87
Atopy
Presence 7 49 NS 7 49 NS
Absence 8 72 13 67
Asthma 3.73±2.0 5.76±6.0 0.021 4.78±3.0 5.70±6.1 NS
duration (yr)
Baseline 81.0±23 82.6±25 NS 92.0±21 80.8±26 NS
FEV1 (%)
PC20 metha- 1.80±0.6 11.5±2.9 0.001 2.48±0.8 11.9±3.0 0.003
choline (mg/mL)*
Table 3. Prevalences of other autoantibodies based on the results
for specific IgG to CK18 and CK19 in patients with bronchial asth-
ma 
CK, cytokeratin; TGase, tissue transglutaminase; CIC, C1q-binding immune
complex; NS, not significant. *mean±standard error mean.416 Y.-M. Ye, D.-H. Nahm, S.-H. Kim, et al.
from the epithelium and that the altered epithelium becomes
an important source of autacoid mediators, chemokines, and
growth factors, which contribute to ongoing inflammation
(15, 16).
Cytokeratin is a cytoskeletal structure that is expressed
only in epithelial cells. Pairs of keratins seem to be consis-
tently co-expressed in different types of epithelial cells. Thus,
CK8, CK18, and CK19, which were used in this study, have
been found only in simple epithelia, including both bronchial
and lung alveolar epithelial cells (17), which are the major
target tissues of asthma. Previously, CK18 has been identi-
fied as a bronchial epithelial autoantigen that is associated
with non-allergic asthma (12). In isocyanate-induced asthma,
CK18 has been identified as a major diisocyanate-binding
protein (18), and significantly higher levels of serum IgG to
CK19 have been detected (19). CK8 and CK18 contain the
caspase cleavage site and have been reported to undergo marked
re-organization during apoptosis (16). These findings raise
the possibility that fragments of CKs and intracytoplasmic
materials are released to the blood vessels and may play a role
in the formation of circulating autoantibodies, including ANA
and IgG to CKs and TGase.
Recent in vitro studies have indicated that the opsoniza-
tion of extracellular keratin aggregates by IgG-anti-CK auto-
antibodies plays an important role in promoting the phago-
cytosis of cytokeratin aggregates (21). This may relate to our
results, which show that asthma patients with anti-CK18
and anti-CK19 antibodies have higher prevalences of CIC
as well as more severe airway hyperresponsiveness to metha-
choline. These results suggest that persistent airway inflam-
mation in some patients with bronchial asthma results from
a non-IgE-mediated reaction to endogenous or exogenous
antigen, possibly an autoantigen, or to a chronic viral infec-
tion (22). These possibilities are supported by a number of
studies, which have shown that some patients with ASA-
intolerant asthma have elevated markers of autoimmunity
with rheumatic symptoms. Enhanced IgG4 synthesis in asso-
ciation with viral infection and a positive association with
the HLA gene marker have been noted (10, 11). Our previ-
ous study has demonstrated that HLA-DPB1*0301 is a valu-
able gene marker for ASA-intolerant asthma (10). However,
in the present study, no direct relationship was found between
this HLA gene marker and the prevalences of IgG antibodies
to the three CKs, ANA, IgG antibody to TGase, and CIC.
Moreover, none of subjects with these autoantibodies com-
plained of rheumatic symptoms.
Tissue transglutaminase (TGase I) is a member of the Ca2+-
dependent enzymes that catalyze the cross-linking of proteins.
TGase I is expressed in tissues that contain simple epithelia,
such as bronchial epithelia, skin epidermis, liver, gastroin-
testinal tract, kidney, and endothelial cells (23). The induc-
tion and activation of TGase is part of the apoptotic cascade
and plays an effector role in the stabilization of apoptotic
bodies to limit the leakage of intracellular components into
the extracellular space (24). Recently, anti-TGase antibodies
have been found not only in various autoimmune diseases,
such as celiac disease, diabetes mellitus type I, and SLE, but
also in toluene diisocyanate-induced asthma (19). Based on
these findings, we examined the impact of anti-TGase anti-
bodies on persistent airway inflammation in patients with
ASA-intolerant asthma, to evaluate the potential of TGase
as an endogenous antigen. However, the prevalence of IgG
to TGase in patients with ASA-intolerant asthma was <5%,
which was similar to that in ASA-tolerant patients, and it
had no effect on asthma phenotype.
Considering the results of the present study, an autoanti-
body-mediated mechanism for ASA-intolerant asthma appears
to be unlikely. We cannot rule out the possibility that the
existence of anti-CK and anti-TGase autoantibodies is a non-
specific consequence of epithelial injury, since anti-CK18 and
anti-CK19 antibodies have been reported in patients with
various airway diseases, which included non-atopic (13) or
TDI-induced asthma (19), pulmonary fibrosis (25), adeno-
carcinoma (26), and non-airway diseases like an autoimmune
hepatitis (27). Besides, the positivity levels of these autoan-
tibodies were neither high enough nor related to ASA-sen-
sitivity, atopy, asthma duration or baseline FEV1. However,
long-term prospective studies are needed to address whether
autoantibodies cause clinical symptoms of autoimmunity
several years later, have a pathogenic role, or merely reflect
the epiphenomenon of polyclonal immune stimulation.
A mechanism by which IgG antibody to CK could be
involved in the pathogenicity of asthma has been suggested
in the case of hexamethylene diisocyanate-induced asthma.
Inhaled hexamethylene diisocyanate can bind to the CK of
epithelial cells, which may induce T cell and cytokine pro-
duction (18). Considering the clinical features of the patients
with ASA-intolerant asthma enrolled in our study, with most
of the patients having moderate to severe persistent asthma,
we hypothesize that self-antigen or possibly CK-driven im-
mune responses contribute to the development of persistent
airway inflammation in these patients. Patients who are more
susceptible to epithelial damage following airway inflamma-
tion, or who have impaired clearance of apoptotic bodies, may
develop serum IgG antibodies to CK. It is clear from this
study that asthmatics with circulating anti-CK18 and anti-
CK19 autoantibodies suffer from more severe airway hyper-
responsiveness and have more complement-binding immune
complexes. 
The prevalence of IgG to CK18 in non-atopic asthma was
a little lower than that seen in the previous investigation using
immunoblot analysis (13). This difference may be due to the
different antigen and antibody detection methods used; the
ELISA system using recombinant CK was applied in this
study to screen a larger population of patients with ASA-intol-
erant asthma.
In conclusion, we have confirmed the existence of several
autoantibody types, with the highest prevalence of IgG toCirculating Autoantibodies in ASA-intolerant Asthma 417
CK18, IgG to CK19, and CIC in patients with bronchial
asthma, irrespective of ASA sensitivity or atopy. In addition,
the correlation with airway hyperresponsiveness suggests
that anti-CK18 and anti-CK19 autoantibodies are involved
in the persistent airway inflammation of bronchial asthma.
To confirm the role of anti-CK autoantibodies, further stud-
ies are needed to show the presence of autoreactive helper T
cells specific for CKs and the deposition of activated com-
plement components in patients with bronchial asthma. 
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